These results indicate that treatment with AZD1775 plus anti-PD-L1 antibody significantly increases cytotoxic T cell infiltration and enhances the antitumor effects in an in vivo subcutaneous model of SCLC. This evidence concerns the gene CD274 and small cell lung carcinoma.